ストックスクリーナーアプリを入手
8.26
0.60%
-0.05
プレマーケット:
8.25
-0.010
-0.12%
前日終値:
$8.31
開ける：
$8.35
24時間の取引高:
1.08M
Relative Volume:
1.03
時価総額：
$2.56B
収益：
$2.68B
当期純損益:
$-184.45M
株価収益率:
-12.14
EPS:
-0.6805
ネットキャッシュフロー:
$229.23M
1週間 パフォーマンス:
+3.64%
1か月 パフォーマンス:
+2.35%
6か月 パフォーマンス:
+11.17%
1年 パフォーマンス:
+57.63%
1日の値動き範囲:
$8.165
$8.38
1週間の範囲:
$7.69
$8.42
52週間の値動き範囲:
$5.01
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
名前
Amneal Pharmaceuticals Inc
セクター
電話
908-947-3120
住所
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
8.26 | 2.56B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-06 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | アップグレード | Goldman | Sell → Buy |
| 2020-12-14 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-12-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-07-27 | 開始されました | Goldman | Sell |
| 2020-05-12 | アップグレード | Guggenheim | Sell → Neutral |
| 2019-12-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-21 | アップグレード | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-03-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | ダウングレード | SunTrust | Buy → Hold |
| 2018-08-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 開始されました | Morgan Stanley | Overweight |
| 2018-06-22 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Amneal Pharmaceuticals Inc (AMRX) 最新ニュース
Assenagon Asset Management S.A. Decreases Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
Hennessy Advisors Inc. Acquires 106,600 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Is Targeting 70% Of Untapped Biologics In The ‘Golden Era’ Of Biosimilars - Citeline News & Insights
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year? - MSN
FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Driven by Rising Allergy Prevalence; AI Driving Market TransformationTechnavio - The Malaysian Reserve
Amneal expects to meet or top annual guidance - MSN
Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2024 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals Maintains Transparency with SEC Filing - TipRanks
JPMorgan Chase & Co. Grows Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Insider Sell: Gautam Patel Sells 62,590 Shares of Amneal Pharmac - GuruFocus.com
Amneal Pharmaceuticals director Patel sells $501,345 in stock By Investing.com - Investing.com Canada
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel Sells 62,590 Shares - MarketBeat
The 3.1% return this week takes Amneal Pharmaceuticals' (NASDAQ:AMRX) shareholders three-year gains to 74% - Simply Wall St
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Testosterone Replacement Therapy Market to Grow by USD 461 Million (2025-2029), Driven by Awareness Initiatives on Hypogonadism and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Amneal (AMRX) Upgraded to Strong Buy: Here's Why - MSN
Amneal Sues Sandoz to Block Copies of New Parkinson's Drug (1) - Bloomberg Law
Amneal Calls Teva's IP Delisting Panic 'Theatrical Distraction' - Law360
Amneal Pharmaceuticals director Gautam Patel sells $139,454 in stock By Investing.com - Investing.com Nigeria
Insider Selling: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Sells 17,410 Shares of Stock - MarketBeat
Amneal Pharmaceuticals director Gautam Patel sells $139,454 in stock - Investing.com India
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices - Benzinga
Here’s Why Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
Jane Street Group LLC Has $681,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Large Decrease in Short Interest - MarketBeat
Geode Capital Management LLC Purchases 378,136 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Barclays PLC Buys 169,756 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:AMRX) - MarketBeat
Epinephrine Autoinjector Market Growth, Trends & Forecast - openPR
State Street Corp Boosts Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
82,596 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Acquired by Wellington Management Group LLP - MarketBeat
Teva loses US appeal to keep inhaler patents on FDA protected drug list - Reuters
Amneal Pharmaceuticals (NASDAQ:AMRX) Rating Lowered to "Buy" at StockNews.com - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 4.5%Here's What Happened - MarketBeat
Teva Makes Two Inhalers Free For Charity Amid Ongoing Patent Battle With Amneal - News & Insights
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Average Price Target from Analysts - MarketBeat
BNP Paribas Financial Markets Sells 402,852 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals' SWOT analysis: generic drug maker's stock poised for growth - Investing.com Australia
Parkinson's Disease Market to Reach New Heights in Growth - openPR
SERD Therapeutics Market Key Players AnalysisAmneal - openPR
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Driven by Rising Allergy Prevalence and AI-Powered Market TransformationTechnavio - The Malaysian Reserve
Jacobs Levy Equity Management Inc. Sells 189,881 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Charles Schwab Investment Management Inc. Buys 202,863 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals Inc (AMRX) 財務データ
収益
当期純利益
現金流量
EPS
0.94%
0.08%
大文字化:
|
ボリューム (24 時間):